The results showed a similar trend in the changes in LCFAs in IMQ-treated WT and Tcrd−/− mice compared to the metabolic changes in LCFAs in psoriasis patients receiving pretherapy and posttreatment with anti-IL-17A mAb. Here, IL17A is linked to psoriasis.